Eric Meissner is an Infectious Disease physician affiliated with Medical University of South Carolina. OpenAlex indexes 120 publications with 2,615 citations (h-index 27).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingMedicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
45.5%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor15.6%Dovato47%Tivicay45%Cabenuva9%Part D<11 patientsProtease Inhibitor10.2%Prezista39%Prezcobix27%Ritonavir22%Darunavir12%Part D<11 patients+ 4 more classes in this area
Cardiovascular
40.8%Statin18.6%Rosuvastatin Calcium60%Atorvastatin Calcium23%Pravastatin Sodium17%Part D<11 patientsCalcium channel blocker12.5%Amlodipine Besylate76%Diltiazem 24hr Er (Cd)13%Amlodipine-Valsartan10%Part D<11 patients+ 4 more classes in this area
Nervous system
6.7%gamma-Aminobutyric Acid A Receptor Positive Modulator1.9%Zolpidem Tartrate100%Part D<11 patientsAntihistamine1.3%Hydroxyzine Hcl100%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2016–2023 per NIH RePORTER. The latest:
- Project 2: Dissection of Type-III Interferon Signaling in iPSC-Derived Hepatocytes
Medical University of South Carolina
FY2023$171,110P20GM130457 - Project 2: Dissection of Type-III Interferon Signaling in iPSC-Derived Hepatocytes
Medical University of South Carolina
FY2022$255,813P20GM130457 - Project 2: Dissection of Type-III Interferon Signaling in iPSC-Derived Hepatocytes
Medical University of South Carolina
FY2021$264,202P20GM130457
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Tanya Turan, MD
Medical University of South Carolina
Michael Zile, MD
Medical University of South Carolina
Jacobo Mintzer, MD
Medical University of South Carolina
Marc Chimowitz, MD
Medical University of South Carolina
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”